CXCR4 Antagonist AMD3100 Accelerates Impaired Wound Healing in Diabetic Mice
- Nishimura, Yukihide
- Ii, Masaaki
- Qin, Gangjian
- Hamada, Hiromichi
- Asai, Jun
- Takenaka, Hideya
- Sekiguchi, Haruki
- Renault, Marie-Ange
- Jujo, Kentaro
- Katoh, Norito
- Kishimoto, Saburo
- Ito, Aiko
- Kamide, Christine
- Kenny, John
- Millay, Meredith
- Misener, Sol
- Thorne, Tina
- Losordo, Douglas W.
DOIAbstract
The antagonism of CXC-chemokine receptor 4 (CXCR4) with AMD3100 improves cardiac performance after myocardial infarction by augmenting the recruitment of endothelial progenitor cells (EPCs) from the bone marrow to the regenerating vasculature. We investigated whether AMD3100 may accelerate diabetes-impaired wound healing through a similar mechanism. Skin wounds were made on the backs of leptin receptor-deficient mice and treated with AMD3100 or saline. Fourteen days after treatment, wound closure was significantly more complete in AMD3100-treated mice (AMD3100: 87.0±2.6%, saline: 33.1±1.8%; P<0.0001) and was accompanied by greater collagen fiber formation, capillary density, smooth muscle–containing vessel density, and monocyte/macrophage i...
Add to ORKG